


**AGC Biologics Launches Bispecific Antibody Development and Manufacturing Project
– Advancing Next-Generation Biopharmaceuticals in Japan through Global Collaboration –**

Tokyo, May 26, 2026—AGC Biologics, Inc., the biopharmaceutical CDMO^{*1} subsidiary of AGC (AGC Inc.; Headquarters: Tokyo; President: Yoshinori Hirai), has launched a bispecific antibody process development and manufacturing project, with activities commencing in May 2026. The project is being conducted in collaboration with Novolty Nobility, a biotechnology company based in South Korea.

Building on prior achievements in cell line development and the establishment of a Master Cell Bank (MCB)^{*2} at the AGC Group’s Copenhagen facility in Denmark, the project will advance to GMP^{*3} manufacturing at the Chiba facility in Japan.

Conceptual Illustration of a Bispecific Antibody



AGC Biologics Chiba Facility



The bispecific antibody targeted in this project, NN4101, is intended for the treatment of retinal neovascular diseases, in which abnormal blood vessel formation in the retina leads to vision impairment. As a “first-in-class” medicine with a novel mechanism of action distinct from conventional therapies, it has the potential to provide a new treatment option. At the same time, the structural complexity of bispecific antibodies requires advanced technologies and stringent quality control across both process development and manufacturing.

Through seamless technology transfer from the Copenhagen facility to the Chiba facility, AGC Biologics has established an integrated framework that supports both process development and GMP manufacturing. Leveraging its network of cGMP-compliant facilities^{*4} across Japan, the United States, and Europe, the company maximizes synergies across its global operations. This enables AGC Biologics to provide flexible manufacturing solutions tailored to customers’ development and production needs by utilizing the most appropriate facility within its network.

Under its medium-term management plan, [***AGC plus-2026***](#), the AGC Group has identified “Well-being” as one of the key social values to be created through its products and technologies. Going forward, AGC will continue to provide high-quality process development and manufacturing services globally across a wide range of modalities, contributing to safe, secure, and healthy lives for people around the world through its life science business.


<Media inquiries>

AGC Inc., Corporate Communications & Investor Relations Division [Contact form](#)

Notes

- *1 CDMO (Contract Development and Manufacturing Organization): A company that provides contract development and manufacturing services for pharmaceuticals.
- *2 Master Cell Bank (MCB): A collection of well-characterized cells stored under controlled conditions, serving as the starting point for biopharmaceutical production and ensuring consistent quality and reproducibility.
- *3 GMP (Good Manufacturing Practice): Standards for the manufacturing and quality control of pharmaceuticals.
- *4 cGMP (Current Good Manufacturing Practice): GMP standards based on the latest scientific knowledge and regulatory requirements.

AGC Group CDMO business sites and supported modalities



<Media inquiries>

AGC Inc., Corporate Communications & Investor Relations Division [Contact form](#)